Reza Bayat Mokhtari | Molecular Biology | Editorial Board Member

Published on by Medical Lab Scientist

Dr. Reza Bayat Mokhtari | Molecular Biology | Editorial Board Member

Director | Association of Clinical Immunology and Cancer Research | United States

Dr. Reza Bayat Mokhtari is a research-intensive biomedical scientist recognized for significant contributions to oncology and translational medicine, with a documented impact of 4,475 citations, an h-index of 20, and an i10-index of 30. The research portfolio focuses on molecular mechanisms of cancer progression, tumor microenvironment dynamics, and resistance to therapy, particularly in lung, breast, pancreatic, hepatic, and neuroendocrine malignancies. Core scientific contributions include studies on Hippo–YAP/TAZ signaling, Agrin-driven oncogenic processes, cancer stem cell regulation, hypoxia-associated pathways, and rational combination and repurposing strategies to improve immunotherapy outcomes. This body of peer-reviewed work bridges fundamental cancer biology with clinically relevant translational models, supporting biomarker development and precision oncology approaches. Overall, the scholarly output reflects sustained productivity, interdisciplinary scope, and measurable influence within the cancer research community.

Citation Metrics (Google Scholar)

6000

4500

3000

1500

0

 

4475
Citations

20
h-index

30
i10-index

Citations

h-index

i10-index

Featured Publications

Heming Li | Molecular Biology | Research Excellence Award

Published on by Medical Lab Scientist

Dr. Heming Li | Molecular Biology | Research Excellence Award

Doctor | The first hospital of China Medical University | China

Dr. Heming Li is an oncology clinician-scientist whose research has generated 1,045 citations across 37 scientific documents with an h-index of 17, reflecting a sustained impact on translational cancer science. His work centers on liquid biopsy innovations, particularly circulating tumor cells (CTCs), tumor invasion and metastasis, and immunotherapy biomarkers in lung, gastric, and hepatobiliary cancers. Dr. Li is recognized for pioneering one of China’s earliest and most sensitive cell-surface vimentin (CSV)–based CTC detection platforms, integrating negative and positive enrichment to enhance diagnostic accuracy, reduce costs, and enable real-time monitoring of tumor evolution. His research spans EMT regulation, immune escape, metabolic reprogramming, and multi-omics characterization of metastatic pathways, leading to first-author and corresponding-author publications in high-impact journals such as The Lancet, Journal of Hematology & Oncology, Journal of Experimental & Clinical Cancer Research, Molecular Cancer, Cancer Letters, and Cell Death & Disease. He has elucidated mechanisms including IGF-IR signaling, KDM4A/STAT3-driven tumor progression, ICAM-1-mediated microenvironmental adaptation, and PD-L1 expression on CSV⁺ CTCs as a prognostic marker in gastric cancer. His recent studies have also advanced understanding of FGL1 as an immune checkpoint target and the biological significance of TROP2 in cancer therapeutics. As principal investigator, he has secured major national and provincial funding, including NSFC General and Young Programs, to study CTC-based biomarkers, immunotherapy prediction models, and metastasis-driving pathways. Through sustained contributions across liquid biopsy technology, molecular oncology, and clinically actionable biomarker development, Dr. Li has established a leading research profile shaping the future of precision cancer care.

Profile: Scopus  

Featured Publications